Comparative efficacy between glimepiride and metformin in preventing progression of prediabetes to type 2 diabetes.docVIP

Vol.3, No.3, 129-133 (2013) Journal of Diabetes Mellitus /10.4236/jdm.2013.33019 Comparative efficacy between glimepiride and metformin in preventing progression of * prediabetes to type 2 diabetes Udaya M. Kabadi University of Iowa, Iowa City, USA; ukabadi@ Received 16 May 2013; revised 18 June 2013; accepted 26 June 2013 Copyright ? 2013 Udaya M. Kabadi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT group and 47 ± 5 months in subjects receiving glimepiride. FPG and HbA1c levels promptly returned to 100 mg/dl and 5.7% on increasing daily dose of both metformin (1000 - 1500 mg) and glimepiride (2 - 4 mg). The glycemic control was maintained till the end of observation period. None of the subjects in either group manifested a cardiovascular event nor any of the subjects died during the period of observation. Conclu- sion: Glimepiride may be more effective in de- laying the progression of prediabetes to diabe- tes in non-obese subjects in comparison to metformin in obese subjects with no significant difference in cardiovascular morbidity or overall mortality. Background: Several recent studies have shown that treatment with therapeutic lifestyle changes, and/or several drugs retard progression of pre- diabetes to type 2 diabetes. However, none of these studies used a Sulfonylurea (SU), al- though in UKPDS, SUs delayed the progression of hyperglycemia and several subjects would have been categorized as having prediabetes by present diagnostic criteria. Thus, SUs may have delayed the progression in this group as well. Objective: Therefore, we examined comparative efficacy of glimepiride and metformin in pro- gression to diabetes in subjects with prediabe- tes. Methods: Twenty men and 18 women ages